Immunovant, Inc. (IMVT) Stock Forecast
IMVT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.41 / 5 from 17 analysts
- Price target
- $48.88 average of analyst targets
- Upside to target
- +82.8% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.73
- 52-week range
- $18.74 – $44.96
IMVT analyst ratings
17 analystsNumber of analysts at each rating.
IMVT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMVT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.72 | −$0.76 | −$0.70 | −$0.65 | −11.4% | 3 |
| Next quarter (Dec '26) | −$0.67 | −$0.77 | −$0.53 | −$0.54 | −24.9% | 3 |
| Current fiscal year (FY2027) | −$2.84 | −$3.05 | −$2.52 | −$2.47 | −15.1% | 5 |
| Next fiscal year (FY2028) | −$2.75 | −$3.21 | −$2.38 | −$2.84 | +3.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMVT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Next quarter (Dec '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 13 |
| Next fiscal year (FY2028) | $36.8M | $0 | $206.4M | 0.0% | 14 |
IMVT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMVT revenue: reported and forecast
IMVT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.53 | −$0.53 | −$0.53 | −$0.73 | −$0.72 | +37.3% | 0 up · 1 down |
| Next quarter (Dec '26) | −$0.45 | −$0.45 | −$0.45 | −$0.74 | −$0.67 | +50.5% | 0 up · 1 down |
| Current fiscal year (FY2027) | −$2.52 | −$2.58 | −$2.84 | −$2.84 | −$2.84 | +12.9% | 0 up · 3 down |
| Next fiscal year (FY2028) | −$2.40 | −$2.50 | −$2.22 | −$2.50 | −$2.75 | +14.7% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMVT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMVT beat in 5 of 12.
What analysts expect from IMVT
17 analysts cover Immunovant; their consensus rating is buy (4.41 on a 1–5 scale, where 5 is a strong buy). The average price target is $48.88, 82.8% above the latest close of $26.73. Analysts expect earnings of −$2.84 per share for FY2027, −15.1% from a year earlier. For FY2028 the average estimate is −$2.75 per share on revenue of $36.8 million. Immunovant beat the EPS estimate in 5 of the last 12 quarters.
Related: IMVT income statement, IMVT key metrics, IMVT chart. See the IMVT stock overview for the latest quote and news.
IMVT forecast FAQ
What is Immunovant's price target?
The average analyst price target for Immunovant is $48.88, 82.8% above the latest close of $26.73.
Is Immunovant a buy, hold or sell?
Of 17 analysts covering Immunovant, 11 rate it a strong buy, 2 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immunovant's EPS forecast?
Analysts forecast −$2.84 per share for FY2027 (range −$3.05 to −$2.52); for FY2028 the estimate is −$2.75.
When does Immunovant report earnings?
Immunovant is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.73.
Does Immunovant usually beat earnings estimates?
Immunovant reported EPS at or above the analyst estimate in 5 of the last 12 quarters.